Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pancreatic cancer

FDG-PET is not useful in early pancreatic cancer diagnosis

Better tools for early detection and accurate staging of pancreatic cancer are needed. The role of 18F-fluorodeoxyglucose (FDG)-PET in this setting is controversial. The results of a large retrospective study analyzing the value of FDG-PET in the diagnosis of pancreatic ductal adenocarcinoma are discussed here.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J. Natl Compr. Canc. Netw. 10, 703–713 (2012).

    CAS  Article  Google Scholar 

  2. 2

    Friess, H. et al. Diagnosis of pancreatic cancer by 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Gut 36, 771–777 (1995).

    CAS  Article  Google Scholar 

  3. 3

    Tang, S. et al. Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur. J. Radiol. 78, 142–150 (2011).

    Article  Google Scholar 

  4. 4

    Matsumoto, I. et al. 18-Fluorodeoxyglucose positron emission tomography does not aide in diagnosis of pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol.

  5. 5

    Dibble, E. H. et al. PET/CT of cancer patients: part 1, pancreatic neoplasms. AJR Am. J. Roentgenol. 199, 952–967 (2012).

    Article  Google Scholar 

  6. 6

    Kamisawa, T. et al. FDG-PET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 57, 447–450 (2010).

    PubMed  Google Scholar 

  7. 7

    Hartwig, W. et al. CA19–9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann. Surg. Oncol.–1.

  8. 8

    Kittaka, H. et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in predicting the pathologic response to preoperative chemoradiation therapy in patients with resectable T3 pancreatic cancer. World J. Surg. 37, 169–178 (2013).

    Article  Google Scholar 

  9. 9

    Cameron, K. et al. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom. Imaging 36, 463–471 (2011).

    Article  Google Scholar 

  10. 10

    Treglia, G., Castaldi, P., Rindi, G., Giordano, A. & Rufini, V. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42, 80–87 (2012).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Markus W. Büchler.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Strobel, O., Büchler, M. FDG-PET is not useful in early pancreatic cancer diagnosis. Nat Rev Gastroenterol Hepatol 10, 203–205 (2013).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing